| Year |
Citation |
Score |
| 2023 |
Goodwin GM, Aaronson ST, Alvarez O, Atli M, Bennett JC, Croal M, DeBattista C, Dunlop BW, Feifel D, Hellerstein DJ, Husain MI, Kelly JR, Lennard-Jones MR, Licht RW, Marwood L, ... ... Tsai J, et al. Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders. PMID 36740140 DOI: 10.1016/j.jad.2023.01.108 |
0.307 |
|
| 2021 |
Loebel A, Koblan KS, Tsai J, Deng L, Fava M, Kent J, Hopkins SC. A Randomized, Double-blind, Placebo-controlled Proof-of-Concept Trial to Evaluate the Efficacy and Safety of Non-racemic Amisulpride (SEP-4199) for the Treatment of Bipolar I Depression. Journal of Affective Disorders. PMID 34614447 DOI: 10.1016/j.jad.2021.09.109 |
0.34 |
|
| 2018 |
Raison CL, Pikalov A, Siu C, Tsai J, Koblan K, Loebel A. C-reactive protein and response to lurasidone in patients with bipolar depression. Brain, Behavior, and Immunity. PMID 30102967 DOI: 10.1016/j.bbi.2018.08.009 |
0.335 |
|
| 2017 |
Forester BP, Sajatovic M, Tsai J, Pikalov A, Cucchiaro J, Loebel A. Safety and Effectiveness of Long-Term Treatment with Lurasidone in Older Adults with Bipolar Depression: Post-Hoc Analysis of a 6-Month, Open-Label Study. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. PMID 29146409 DOI: 10.1016/j.jagp.2017.08.013 |
0.308 |
|
| 2017 |
Tsai J, Thase ME, Mao Y, Ng-Mak D, Pikalov A, Loebel A. Lurasidone for major depressive disorder with mixed features and anxiety: a post-hoc analysis of a randomized, placebo-controlled study. Cns Spectrums. 1-10. PMID 28357969 DOI: 10.1017/S1092852917000074 |
0.314 |
|
| 2017 |
Swann AC, Fava M, Tsai J, Mao Y, Pikalov A, Loebel A. Lurasidone for major depressive disorder with mixed features and irritability: a post-hoc analysis. Cns Spectrums. 1-8. PMID 28300012 DOI: 10.1017/S1092852917000232 |
0.306 |
|
| 2017 |
Pikalov A, Goldberg J, Siu C, Mao Y, Tsai J, Loebel A. Lurasidone for the treatment of major depressive disorder with mixed features: do manic symptoms moderate treatment response? European Neuropsychopharmacology. 27: S831-S832. DOI: 10.1016/S0924-977X(17)31499-2 |
0.314 |
|
| 2016 |
Iosifescu D, Tsai J, Hsu J, Pikalov A, Loebel A. Efficacy of lurasidone in the treatment of major depression with mixed features: the value of early improvement as a predictor of short-term response during treatment of bipolar depression with lurasidone European Neuropsychopharmacology. 26: S414. DOI: 10.1016/S0924-977X(16)31381-5 |
0.332 |
|
| 2016 |
Nierenberg A, Tsai J, Mao Y, Pikalov A, Suppes T, Loebel A. Efficacy Of Lurasidone In Major Depression With Mixed Features: Pattern Of Improvement In Depressive And Manic Symptoms European Psychiatry. 33: S423-S423. DOI: 10.1016/j.eurpsy.2016.01.1525 |
0.319 |
|
| 2015 |
Iosifescu D, Tsai J, Pikalov A, Kroger H, Cucchiaro J, Loebel A. P.2.d.018 The value of early improvement as a predictor of short-term response during treatment of bipolar depression with lurasidone European Neuropsychopharmacology. 25: S421. DOI: 10.1016/S0924-977X(15)30560-5 |
0.303 |
|
| 2014 |
Thase M, Tsai J, Kroger H, Pikalov A, Cucchiaro J, Loebel A. P.2.d.052 Lurasidone treatment for bipolar I depression: effect on core depression symptoms European Neuropsychopharmacology. 24: S444-S445. DOI: 10.1016/S0924-977X(14)70710-2 |
0.315 |
|
| Show low-probability matches. |